PMID- 20163203
OWN - NLM
STAT- MEDLINE
DCOM- 20100812
LR  - 20171116
IS  - 1502-7708 (Electronic)
IS  - 0036-5521 (Linking)
VI  - 45
IP  - 5
DP  - 2010 May
TI  - Prediction of 6-thioguanine nucleotides levels in Japanese patients with 
      inflammatory bowel diseases during long-term thiopurine administration.
PG  - 608-14
LID - 10.3109/00365521003642559 [doi]
AB  - BACKGROUND: The monitoring of 6-thioguanine nucleotides (6-TGN) levels is 
      warranted during thiopurine therapy for patients with inflammatory bowel 
      diseases. AIMS: The aim of this study was to elucidate the parameters that can 
      predict the 6-TGN levels among Japanese patients with inflammatory bowel diseases 
      undergoing thiopurine therapy. MATERIAL AND METHODS: The 6-TGN levels were 
      measured in 54 patients with inflammatory bowel diseases (32 with ulcerative 
      colitis and 22 with Crohn's disease), who had been administered azathioprine or 
      6-mercaptopurine for more than 90 days. Possible correlations between the 
      hematologic parameters and 6-TGN levels were investigated. The clinical and 
      hematologic variables were evaluated to determine the 6-TGN levels of less than 
      or over 235 pmol/8 x 10(8) RBCs. RESULTS: The 6-TGN levels correlated 
      significantly with changes in the mean corpuscular volume (R = 0.423, p = 0.001) 
      and the lymphocyte counts (R = -0.280, p = 0.04). A multivariate analysis 
      revealed changes in the mean corpuscular volume (OR: 1.22, 95% CI: 1.07-1.40) and 
      hemoglobin levels (OR: 0.59, 95% CI: 0.35-0.99) to be factors predictive of the 
      6-TGN levels. An increase in the mean corpuscular volume of 3.5 fl was determined 
      to be the most preferable cut-off value to distinguish patients with 6-TGN >or= 
      235 pmol/8 x 10(8) RBCs from those with a lower concentration. CONCLUSIONS: 
      Changes in the mean corpuscular volume are considered to be predictive of the 
      6-TGN levels in patients with inflammatory bowel diseases receiving thiopurine 
      therapy.
FAU - Kochi, Shuji
AU  - Kochi S
AD  - Department of Medicine and Clinical Science, Graduate School of Medical Sciences, 
      Kyushu University, Higashi-ku, Fukuoka, Japan. decorin@intmed2.med.kyushu-u.ac.jp
FAU - Matsumoto, Takayuki
AU  - Matsumoto T
FAU - Esaki, Motohiro
AU  - Esaki M
FAU - Jo, Yukihiko
AU  - Jo Y
FAU - Iida, Mitsuo
AU  - Iida M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Biomarkers, Pharmacological)
RN  - 0 (Nucleotides)
RN  - E7WED276I5 (Mercaptopurine)
RN  - FTK8U1GZNX (Thioguanine)
RN  - MRK240IY2L (Azathioprine)
SB  - IM
MH  - Adult
MH  - Azathioprine/*administration & dosage
MH  - Biomarkers, Pharmacological/blood
MH  - Chi-Square Distribution
MH  - Erythrocyte Volume
MH  - Female
MH  - Humans
MH  - Inflammatory Bowel Diseases/*drug therapy
MH  - Japan
MH  - Logistic Models
MH  - Male
MH  - Mercaptopurine/administration & dosage
MH  - Nucleotides/*blood
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Statistics, Nonparametric
MH  - Thioguanine/*blood
EDAT- 2010/02/19 06:00
MHDA- 2010/08/13 06:00
CRDT- 2010/02/19 06:00
PHST- 2010/02/19 06:00 [entrez]
PHST- 2010/02/19 06:00 [pubmed]
PHST- 2010/08/13 06:00 [medline]
AID - 10.3109/00365521003642559 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2010 May;45(5):608-14. doi: 10.3109/00365521003642559.